Clinical Laserthermia Systems

Håkan Rosqvist has 15 years of experience from leading positions at Sony Mobile Communications. Since 2016, Håkan has also held several executive roles within finance, financial controlling, and business development, and which also included capital raising, at various growth companies, including Tretton37, Spiideo and Evidensia.

'We are currently in a very exciting and eventful phase where Håkan can contribute greatly with his solid experience and history of developing growth companies until a permanent CFO is appointed. I am very grateful for Katarina's efforts during this time, which have contributed to the establishment of a robust foundation and plan for the continued journey ahead,” says Dan J. Mogren, CEO, CLS.

The recruitment of a permanent CFO is ongoing.

For further information, please contact:


Dan J. Mogren, CEO Clinical Laserthermia Systems AB

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se